For anyone that's interested, I've been following this since 2005. Although my memory is often flawed this is a synopsis of how I recall the development over the years.
What I remember is the drug started with the development of CT100 (I think that's right) that D. Platt made at a previous company prior to 2000. That was made from orange peels. This is the compound that eventually ended up in LaJolla's control. It had the problem of the molecule size being too difficult to control which is why, as I remember, LaJolla stopped investigating it.
Platt started Pro Pharmaceuticals around 2000 and they developed another carbohydrate compound they called Davanat (named after the two first names of the developers). Pro-Pharma changed it's name to Galectin somewhere around 2010 or so. Davanat was renamed GM-CT-01 after Traber took over. It's made out of guar, which I think they use in making ice cream, anyway, some sort of bean. That was better than the CT100, more consistent in molecular size. They later came up with the GR-MD-02 which I think they use Apple peels to make. The rest is history.
They are trying to get an oral version but I don't think humans digest long chain carbohydrates as well as animals, so the pre-clinical stuff may not mean much. Could be a good veterinary medicine someday though.
Liver treatment right now is the Holy Grail. No approved competition and little competition in the wings. Low bar for approval for the first one through the gate. Psoriasis was nothing more than a Hail Mary that might have had some value as a product to sell to someone who wanted to compete in that game. The melanoma trial may hold some reasonable value if successful, but if the FX trial is a bust then I don't see much reason to stick around.
Market Data 
Markets 
AI
